BiotechTube
Elypta

Elypta

Stockholm, Sweden· Est.
elypta.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $23.5M

Overview

Elypta is an innovative diagnostics company developing a novel, metabolism-focused liquid biopsy platform centered on the GAGome. Its core technology uses mass spectrometry to quantify glycosaminoglycans in biofluids, with applications in multi-cancer early detection, recurrence monitoring for renal cell carcinoma, and risk stratification. The company is in the clinical validation and study phase, actively publishing data and engaging in large-scale European projects like PREDI-LYNCH, positioning itself in the high-growth liquid biopsy market.

Oncology

Technology Platform

Metabolism-based liquid biopsy platform measuring the GAGome (glycosaminoglycan profile) in blood and urine using standardized MIRAM® Kits and UHPLC-MS/MS, analyzed with machine learning for cancer detection.

Funding History

2
Total raised:$23.5M
Series A$21M
Seed$2.5M

Opportunities

The large and growing liquid biopsy market, particularly for multi-cancer early detection and minimal residual disease monitoring, presents a multi-billion dollar opportunity.
Elypta's unique focus on metabolic biomarkers could allow it to detect cancers missed by other methods and to partner with companies offering complementary genomic tests.
Initial focus on clear clinical niches like RCC surveillance provides a viable path to initial market entry and revenue.

Risk Factors

Key risks include failure to validate clinical utility in larger trials, intense competition from well-funded liquid biopsy companies, and challenges in achieving regulatory approval and payer reimbursement for a novel biomarker class.
As a private, pre-revenue company, it also faces execution and financing risks.

Competitive Landscape

Elypta competes in the crowded liquid biopsy space against major players like Grail (Illumina), Exact Sciences, Guardant Health, and Freenome, which primarily use cell-free DNA or methylation patterns. Its key differentiation is its metabolism-based GAGome platform, which may detect different biological signals. It faces competition from other metabolomic approaches and must prove superior or complementary performance to gain market share.

More companies in Sweden →